Remicade (infliximab) denied as not medically necessary by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UHC Calls This "Not Medically Necessary" — and What That Really Means

When UnitedHealthcare denies Remicade (infliximab, J1745) under the medical benefit as "not medically necessary," the denial is almost never about whether infliximab works for your Crohn's, ulcerative colitis, RA, ankylosing spondylitis, or plaque psoriasis. It is a non-medical formulary substitution dressed in medical-necessity language. UHC's Commercial Medical Benefit Drug Policy (effective 02.01.2026) designates Avsola (Q5121) and Inflectra (Q5103) as the preferred infliximab products and explicitly states that members on Remicade "will be required to change therapy" absent exception criteria. The denial letter typically cites the policy's three-prong escape hatch and tells you that you have not satisfied any of them.

The three prongs are narrow but real: (1) a documented ≥14-week trial of Inflectra or Avsola with "minimal clinical response"; (2) a physician attestation that response would be expected to be superior with reference Remicade than with the biosimilars; or (3) documented intolerance, contraindication, or adverse event to the preferred biosimilars combined with attestation that the same event would not be expected with Remicade. UHC adjudicates these through Optum Rx clinical review even though the claim hits the medical (J-code) benefit, because UHC's specialty pharmacy infusion vendor is Optum Specialty Pharmacy / Optum Infusion. Appeals letters routed to the wrong unit (commercial appeals queue vs. Optum clinical pharmacy review) stall — confirm the correct fax/portal endpoint on the denial letter.

ERISA imposes hard procedural duties UHC routinely under-satisfies. Under 29 CFR §2560.503-1(g)(1)(v)(A), the denial must identify the specific internal rule or clinical guideline relied on, and §2560.503-1(h)(3)(iii) requires access to the full claim file on request — including the UHC Medical Policy version and any Optum clinical reviewer notes. Demand both in writing. For non-grandfathered ACA plans, 45 CFR §156.122(c) preserves continuity protections when a drug is removed mid-plan-year, which is the posture for members switched off Remicade. Pinto v. Aetna Life Insurance Co., 535 F. App'x 745 (10th Cir. 2013), confirmed the insurer bears the burden of articulating a coherent clinical basis — boilerplate "biosimilar is equivalent" language without engagement with the prescriber's attestation is arbitrary and capricious.

If the patient has established maintenance on Remicade with documented remission, the strongest appeal frame is non-medical switching risk — cite the NOR-SWITCH extension data and ACG/AGA position statements warning against forced switching in stable IBD patients, attach trough levels and antibody-to-infliximab (ATI) results, and invoke the §156.122 continuity argument.

Tactical tip: Pair the prescriber's prong-2 attestation with immunogenicity data — specifically a negative ATI result on Remicade and documented therapeutic trough. UHC reviewers cave on attestations backed by lab evidence; pure narrative attestations get denied. File simultaneously with your state DOI; for self-funded ERISA plans, route to DOL EBSA at 1-866-444-3272.